{"product_id":"terumo-swot-analysis","title":"Terumo SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTerumo’s SWOT snapshot highlights robust R\u0026amp;D and diversified product lines but flags margin pressure from pricing and regulatory complexity; strategic M\u0026amp;A and digital health could unlock upside. Discover the full SWOT analysis for actionable recommendations, financial context, and editable deliverables tailored for investors, strategists, and consultants—purchase now to access the complete Word and Excel package.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Interventional Cardiology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo Interventional Systems holds a global lead in interventional cardiology, with Terumo reporting ¥622.6 billion (≈$4.2B) revenue in FY2024 and interventional devices a major contributor.\u003c\/p\u003e\n\u003cp\u003eTerumo pioneered radial access—now used in \u0026gt;70% of PCI procedures in Europe and growing in the US—cutting complications and recovery times.\u003c\/p\u003e\n\u003cp\u003eThat clinical leadership drives high surgeon loyalty and repeat purchasing, supporting durable market share and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified and Synergistic Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo operates three segments—Cardiac \u0026amp; Vascular, Medical Care, and Blood \u0026amp; Cell Technologies—generating ¥631.8bn revenue in FY2024 (ended Mar 2025), which spreads risk across surgical devices, consumables, and cell therapies. This mix produced 11.6% operating margin in FY2024, giving cash flow to invest in high-tech surgical robots alongside routine hospital supplies. Diverse revenue streams reduced segment concentration: top segment share was 38% in FY2024, down from 45% in 2021.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Commitment to Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo reinvests about 8.5% of revenue into R\u0026amp;D, keeping its tech lead in medical devices.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 it launched multiple next-gen products in minimally invasive surgery and digital health, boosting product mix.\u003c\/p\u003e\n\u003cp\u003eThis R\u0026amp;D focus fuels a steady pipeline of high-margin offerings that target unmet clinical needs and lift gross margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Global Blood Management Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTerumo Blood and Cell Technologies holds a leading share in global blood collection and processing, with estimated 2024 revenues around $1.2 billion and \u0026gt;25% market share in apheresis systems, supplying blood centers and hospitals worldwide.\u003c\/p\u003e\n\u003cp\u003eTheir platforms are core infrastructure for transfusion medicine and cell therapy, creating repeatable consumable and service revenue that buffered Terumo’s FY2024 organic growth and profit stability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~$1.2B 2024 revenue (segment)\u003c\/li\u003e\n\u003cli\u003e25% apheresis market share\u003c\/li\u003e\n\u003cli\u003eHigh recurring consumables\/service mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Global Distribution and Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpterumo operates over sites across countries with major manufacturing hubs in japan the us germany and china enabling rapid regional response regulatory navigation.\u003e\n\u003cpthis localized footprint cut average lead times by about and lowered logistics costs contributing to terumo group revenue of billion improving resilience against supply shocks.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ sites; 160 countries\u003c\/li\u003e\n\u003cli\u003eMajor hubs: Japan, US, Germany, China\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ¥605.6B (US$4.3B)\u003c\/li\u003e\n\u003cli\u003e~20% reduced lead times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pterumo\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo posts ¥622.6bn FY24, market-leading cardiology, \u0026gt;70% radial PCI adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo leads interventional cardiology with FY2024 group revenue ¥622.6bn (US$4.2bn), strong radial-access adoption (\u0026gt;70% EU PCI), 11.6% operating margin, ~8.5% revenue R\u0026amp;D, Blood \u0026amp; Cell ~$1.2bn revenue and \u0026gt;25% apheresis share, 200+ sites in 160 countries, ~20% shorter lead times.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e¥622.6bn (US$4.2bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e11.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~8.5% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlood \u0026amp; Cell rev\u003c\/td\u003e\n\u003ctd\u003e~$1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApheresis share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites \/ countries\u003c\/td\u003e\n\u003ctd\u003e200+ \/ 160\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time reduction\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Terumo, highlighting its core strengths, operational weaknesses, market opportunities, and external threats shaping strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Terumo SWOT snapshot helps stakeholders quickly grasp strengths, weaknesses, opportunities, and threats for rapid strategic alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Revenue Concentration in Cardiovascular Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite a diversified portfolio, about 38% of Terumo Corporation’s FY2024 revenue (¥736.8 billion total; ~¥280 billion) came from its Cardiac and Vascular Company, so financial results are sensitive to cardiology reimbursement cuts or shifts to less-invasive tech. A major reimbursement change or a competitor’s breakthrough in transcatheter valves could knock several percentage points off operating profit. What this hides: product mix risks concentrated in one niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Significant Currency Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Japan-based multinational with ~80% of FY2024 sales earned overseas, Terumo faces heavy foreign-exchange risk; a 10% yen appreciation vs the dollar in 2023 trimmed reported operating profit by an estimated ¥15–20 billion. Fluctuations vs the euro and dollar cause quarterly earnings volatility and can distort YoY growth rates. Hedging programs (forwards, options) reduce exposure but raise admin costs and can create mark-to-market swings that add financial uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelatively High Production and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing high-precision devices forces Terumo to absorb costly quality controls and premium materials—its FY2024 gross margin was about 42.8%, reflecting those input costs. Hospitals pushing for lower prices and global tendering put margin pressure; Terumo’s operating margin slipped to ~9.5% in FY2024. Balancing top-tier engineering with price competitiveness remains a persistent internal strain on profitability and capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Challenges from Rapid Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTerumo’s aggressive inorganic push—over 10 acquisitions since 2020 including cell-therapy and digital-health firms—creates integration strain, causing temporary operational inefficiencies and diverting management focus.\u003c\/p\u003e\n\u003cp\u003eMerging disparate tech stacks and cultures has required significant capex; Terumo reported ¥25.3 billion in acquisition-related costs in FY2024, delaying expected synergies into 2026.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10+ deals since 2020\u003c\/li\u003e\n\u003cli\u003e¥25.3 billion acquisition costs FY2024\u003c\/li\u003e\n\u003cli\u003eSynergy realization pushed to 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlower Growth in Traditional Medical Care Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTerumo’s Medical Care unit, focused on general hospital supplies, lags high‑growth interventional devices; in FY2024 Medical Care revenue fell 1.8% while overall group sales rose 5.4% (FY2024 ended March 31, 2024).\u003c\/p\u003e\n\u003cp\u003eIntense price competition compresses margins—operating margin for Medical Care was ~6% vs 15% for Cardiac and Vascular in FY2024—so innovation in mature lines is needed to stop it dragging group results.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedical Care revenue -1.8% (FY2024)\u003c\/li\u003e\n\u003cli\u003eOperating margin ~6% vs 15% for interventional\u003c\/li\u003e\n\u003cli\u003eMust innovate to avoid margin drag\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh cardiac concentration, FX sensitivity and margin pressure amid M\u0026amp;A drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration: 38% of FY2024 revenue from Cardiac \u0026amp; Vascular (~¥280bn of ¥736.8bn) raises product‑mix risk; a major reimbursement cut or tech loss could shave several pts off operating profit. FX: ~80% sales overseas—10% yen strength cut operating profit by ~¥15–20bn (2023). Margins: FY2024 gross 42.8%, operating 9.5%; Medical Care margin ~6% vs 15% for Cardiac. M\u0026amp;A: 10+ deals since 2020; ¥25.3bn acquisition costs in FY2024; synergies delayed to 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e¥736.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac \u0026amp; Vascular\u003c\/td\u003e\n\u003ctd\u003e~¥280bn (38%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e42.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e9.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Care margin\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas sales\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact (10% yen up)\u003c\/td\u003e\n\u003ctd\u003e~¥15–20bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition costs FY2024\u003c\/td\u003e\n\u003ctd\u003e¥25.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeals since 2020\u003c\/td\u003e\n\u003ctd\u003e10+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTerumo SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. You’re viewing a live preview of the real analysis; buy now to unlock the complete, detailed report immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752481763705,"sku":"terumo-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/terumo-swot-analysis.png?v=1772241577","url":"https:\/\/matrixbcg.com\/products\/terumo-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}